Dermatology Times

AUGUST 23, 2023

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Safety 36

Safety Treatments 36

The Dermatology Digest

MAY 17, 2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)

Safety 36

Safety Sustainability Clinic Innovations 36

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. This trial included samples from 313 people on active treatment.

Safety 36

Safety Eczema Dermatology Treatments 36

Dermatology Times

APRIL 12, 2024

Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Safety 36

Safety Treatments 36

The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified. Study author Melinda J.

Safety 36

Safety Eczema Social Media Dermatology 36

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

APRIL 12, 2024

She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment. Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives.

Dermatitis 85

Dermatitis Treatments Safety Management 85

Dermatology Times

SEPTEMBER 6, 2023

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Safety 36

Safety Treatments 36

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

JULY 26, 2024

The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. The post FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced cSCC appeared first on The Dermatology Digest.

Treatments 36

Treatments Surgery Safety Clinic 36

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

The Dermatology Digest

SEPTEMBER 9, 2024

s AISA-021(cilnidipine), a fourth-generation calcium channel antagonist under development for the treatment of Systemic Sclerosis (SSc). We are actively seeking a development partner and investors to support bringing this much-needed treatment to patients.” and Abroad appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Dermatology Injections Innovations 36

Dermatology Times

AUGUST 14, 2024

Omer Ibrahim, MD, discusses the nuances of aesthetic procedures for patients with skin of color and the importance of tailored treatments, safety, and improved clinician education.

Treatments 36

Treatments Safety Education 36

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

Trillium Creek Dermatology

APRIL 30, 2024

As the trees begin to blossom, you too can blossom with a new look thanks to the magic of Botox at Trillium Creek Dermatology, Ohio’s finest skin care facility. Why Choose Trillium Creek Dermatology for Botox? At Trillium Creek Dermatology, we are committed to our patients.

Surgery 36

Surgery Dermatology Wrinkles Injections 36

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

The Dermatology Digest

JUNE 10, 2024

Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin ( Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm 2.

Treatments 36

Treatments Safety Office Clinic 36

Trillium Creek Dermatology

JANUARY 12, 2024

-invasive cosmetic treatments are a great way to achieve your aesthetic goals without undergoing intensive surgery with a long recovery period. The following are some of the most popular non-invasive treatments we offer at Trillium Creek: Botox Botox is one of the most popular and well-known cosmetic treatments.

Treatments 36

Treatments Eyebrow Shaping Chemical Peels Facials 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 16, 2023

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Dermatology Medical 36

Dermatology Times

MAY 13, 2024

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Safety 74

Safety Treatments 74

Dermatology Times

NOVEMBER 12, 2023

Late-breaking data adds important safety and efficacy data for leukotriene receptor antagonists augmentation in chronic urticaria treatment.

Safety 36

Safety Treatments 36

Dermatology Times

AUGUST 9, 2023

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Safety 36

Safety Dermatitis Treatments 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

The Dermatology Digest

AUGUST 30, 2024

Merck is discontinuing the Phase 3 KEYNOTE-630 trial evaluating (pembrolizumab, Keytruda) for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent Data Monitoring Committee (DMC).

Surgery 36

Surgery Safety Therapy Innovations 36

Dermatology Times

JUNE 12, 2024

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dermatitis 36

Dermatitis Treatments Safety 36

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

The Dermatology Digest

JULY 21, 2023

Pandya, MD, Director, Pigmentary Disorders Clinic, Palo Alto Foundation Medical Group, Sunnyvale, California; and Adjunct Professor of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas “This is the most exciting time of my career when it comes to treatment of vitiligo. 2020;396(10244):110-120.

Treatments 36

Treatments Safety Medical Clinic 36

The Dermatology Digest

JULY 16, 2024

is starting its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Celldex Therapeutics, Inc.

Safety 36

Safety Clinic Dermatitis Dermatology 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Clinic Office 74